Literature DB >> 11472424

Oral administration of unmodified colonic but not small intestinal antigens protects rats from hapten-induced colitis.

A Dasgupta1, K V Kesari, K K Ramaswamy, P S Amenta, K M Das.   

Abstract

Colonic administration of a hapten, 2,4,6-trinitrobenzene sulphonic acid (TNBS) has been shown to induce colitis in rats. We are using this model to investigate the role of colonic antigens in the immunopathology. In this study, we show that colitis can be suppressed by oral administration of haptenized colonic antigens prior to the TNBS enema. Moreover, our data suggest that haptenization of the colonic antigens is not essential because oral feeding of non haptenized colonic antigens too protects rats from TNBS-induced colitis. Thus, unmodified colonic antigens may be involved in the induction of oral tolerance, and possibly in the pathogenesis in this model of colitis. Further, we show that the protective immunity or oral tolerance induced by non haptenized colonic antigens can be passively transferred to naïve rats by mesenteric T lymphocytes. Interestingly, oral feeding of small intestinal antigens, haptenized and non haptenized, does not protect rats from colitis, suggesting a specific role for colonic antigens. These data underscore the usefulness of this rat model in the identification of pathogenic antigens in colitis and in the development of therapeutic strategies based on oral tolerance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472424      PMCID: PMC1906096          DOI: 10.1046/j.1365-2249.2001.01539.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

Review 1.  Inflammatory bowel disease (1)

Authors:  D K Podolsky
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

Review 2.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

3.  In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis.

Authors:  T Hibi; M Ohara; K Toda; A Hara; H Ogata; Y Iwao; N Watanabe; M Watanabe; Y Hamada; K Kobayashi
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

4.  Production of immunity and unresponsiveness in the mouse by feeding contact sensitizing agents and the role of suppressor cells in the peyer's patches, mesenteric lymph nodes and other lymphoid tissues.

Authors:  G L Asherson; M Zembala; M A Perera; B Mayhew; W R Thomas
Journal:  Cell Immunol       Date:  1977-09       Impact factor: 4.868

5.  Hapten-induced model of chronic inflammation and ulceration in the rat colon.

Authors:  G P Morris; P L Beck; M S Herridge; W T Depew; M R Szewczuk; J L Wallace
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

6.  Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice.

Authors:  E F Verdù; P Bercik; B Cukrowska; M A Farre-Castany; H Bouzourene; E Saraga; A L Blum; I Corthésy-Theulaz; H Tlaskalova-Hogenova; P Michetti
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

8.  Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis.

Authors:  K M Das; A Dasgupta; A Mandal; X Geng
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

9.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

Authors:  P P Bradley; D A Priebat; R D Christensen; G Rothstein
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

10.  Specificity of antibodies secreted by hybridomas generated from activated B cells in the mesenteric lymph nodes of patients with inflammatory bowel disease.

Authors:  L P Chao; J Steele; C Rodrigues; J Lennard-Jones; J L Stanford; C Spiliadis; G A Rook
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

View more
  6 in total

1.  Effects of appendectomy and oral tolerance on dextran sulfate sodium colitis.

Authors:  Min Yue; Zhe Shen; Chao-Hui Yu; Hua Ye; Yue-Fang Ye; You-Ming Li
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

2.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

3.  Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.

Authors:  Eran Israeli; Eran Goldin; Oren Shibolet; Athalia Klein; Nilla Hemed; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

4.  The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate.

Authors:  Yuefang Ye; Min Yue; Xi Jin; Shaohua Chen; Youming Li
Journal:  Int J Colorectal Dis       Date:  2012-01-14       Impact factor: 2.571

5.  The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in gammadelta T cells in large intestinal mucosa.

Authors:  Yuefang Ye; Xi Jin; Min Yue; Shaohua Chen; Chaohui Yu; Youming Li
Journal:  Int J Colorectal Dis       Date:  2010-06-23       Impact factor: 2.571

6.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.

Authors:  Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.